Regenxbio Inc (NASDAQ: RGNX) kicked off on Tuesday, up 1.65% from the previous trading day, before settling in for the closing price of $12.74. Over the past 52 weeks, RGNX has traded in a range of $10.49-$28.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 72.63%. While this was happening, its average annual earnings per share was recorded 24.86%. With a float of $44.56 million, this company’s outstanding shares have now reached $49.42 million.
The extent of productivity of a business whose workforce counts for 344 workers is very important to gauge. In terms of profitability, gross margin is 42.66%, operating margin of -277.01%, and the pretax margin is -270.91%.
Regenxbio Inc (RGNX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 9.83%, while institutional ownership is 89.90%. The most recent insider transaction that took place on Sep 03 ’24, was worth 115,588. In this transaction Director of this company sold 10,000 shares at a rate of $11.56, taking the stock ownership to the 11,286 shares. Before that another transaction happened on Aug 01 ’24, when Company’s Director sold 10,100 for $13.51, making the entire transaction worth $136,454. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1.41 earnings per share (EPS), higher than consensus estimate (set at -1.52) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.86% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Take a look at Regenxbio Inc’s (RGNX) current performance indicators. Last quarter, stock had a quick ratio of 3.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.27, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
The latest stats from [Regenxbio Inc, RGNX] show that its last 5-days average volume of 0.45 million was inferior to 0.6 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 86.29%. Additionally, its Average True Range was 0.73.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 34.99%, which indicates a significant decrease from 77.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.02% in the past 14 days, which was lower than the 57.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.47, while its 200-day Moving Average is $15.75. Now, the first resistance to watch is $13.43. This is followed by the second major resistance level at $13.92. The third major resistance level sits at $14.35. If the price goes on to break the first support level at $12.51, it is likely to go to the next support level at $12.08. The third support level lies at $11.60 if the price breaches the second support level.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
The company with the Market Capitalisation of 639.99 million has total of 49,256K Shares Outstanding. Its annual sales at the moment are 90,240 K in contrast with the sum of -263,490 K annual income. Company’s last quarter sales were recorded 22,300 K and last quarter income was -52,990 K.
